ArticleBMC ophthalmology2025
Clinicopathological and genetic analysis of orbital solitary fibrous tumors.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo investigate the clinicopathological and genetic characteristics of patients with orbital solitary fibrous tumor (SFT) for clinical reference.
methodsThis single-center retrospective case-series study assessed clinical manifestations, imaging features, treatment, and prognosis of patients with orbital SFT. Immunohistochemical staining and fusion gene detection were also performed.
resultsThe mean age of monocular orbital SFT patients was 38.89 ± 19.69 years (10 males and 8 females). The most common complaint was unilateral proptosis (68%). Tumors were 2.47 ± 0.67 cm in diameter, primarily oval-like (72%), and located in the upper part of the orbit (82%). Immunohistochemical staining results are as follows: STAT6 + (100%), CD99 + (100%), GRIA2 + (100%), ALDH1 + (95%), CD34 + (86%), Bcl-2 + (62%), EMA + (57%), S-100 + (10%), SMA + (10%), CD31 + (0%), Desmin + (0%), P53 + ( 2-44%), Ki-67( 1-10%), VEGFR1 + (100%), VEGFR2 + (100%), VEGFR3 + (0%), PDGFRα + (90%), PDGFRβ + (100%). Among them, CD99 (95%), ALDH1 (90%), and CD34 (86%) were relatively high in moderate and strong positive expression. Bcl-2 staining score of the primary group was higher than that of the recurrent group, and the difference was statistically significant (P < 0.05). Bcl-2 staining score of the benign group was higher than that of the malignant group, and the difference was statistically significant (P < 0.05). Four NAB2-STAT6 fusion variants were detected in 21 paraffin samples, including 1 case each of NAB2ex4-STAT6ex2 and NAB2ex6-STAT6ex16 and 2 cases each of NAB2ex6-STAT6ex17 and NAB2ex7-STAT6ex4.
conclusionOrbital SFT were found in younger cohorts and smaller in size than other SFT. STAT6, CD99, GRIA2, ALDH1, CD34, and Bcl-2 are sensitive indications for orbital SFT, while CD99, ALDH1 and CD34 are more sensitive. High Bcl-2 expression is more common in primary and benign orbital SFT. The orbital SFT gene fusion variants include NAB2ex4-STAT6ex2, NAB2ex6-STAT6ex16, NAB2ex6-STAT6ex17, and NAB2ex7-STAT6ex4. An in-depth clinicopathological study can help explain orbital SFT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.